EA201892096A1 - Нейтрализующие моноклональные антитела к il-25 и их применение - Google Patents

Нейтрализующие моноклональные антитела к il-25 и их применение

Info

Publication number
EA201892096A1
EA201892096A1 EA201892096A EA201892096A EA201892096A1 EA 201892096 A1 EA201892096 A1 EA 201892096A1 EA 201892096 A EA201892096 A EA 201892096A EA 201892096 A EA201892096 A EA 201892096A EA 201892096 A1 EA201892096 A1 EA 201892096A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
monoclonal antibodies
neutralizing monoclonal
neutralizing
compositions
Prior art date
Application number
EA201892096A
Other languages
English (en)
Inventor
Ричард А. Шимкетс
Кристал Лайлз Джексон
Натан Бартлетт
Томас Винсент
Юнхуа Ло
Original Assignee
Эйбоум Корпорейшн
Ричард А. Шимкетс
Кристал Лайлз Джексон
Натан Бартлетт
Томас Винсент
Юнхуа Ло
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйбоум Корпорейшн, Ричард А. Шимкетс, Кристал Лайлз Джексон, Натан Бартлетт, Томас Винсент, Юнхуа Ло filed Critical Эйбоум Корпорейшн
Publication of EA201892096A1 publication Critical patent/EA201892096A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Описаны композиции и способы, относящиеся к связывающим IL-25 молекулам.
EA201892096A 2016-03-16 2017-03-09 Нейтрализующие моноклональные антитела к il-25 и их применение EA201892096A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662309135P 2016-03-16 2016-03-16
PCT/US2017/021578 WO2017160587A1 (en) 2016-03-16 2017-03-09 Neutralizing monoclonal antibodies to il-25 and uses thereof

Publications (1)

Publication Number Publication Date
EA201892096A1 true EA201892096A1 (ru) 2019-08-30

Family

ID=59852393

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892096A EA201892096A1 (ru) 2016-03-16 2017-03-09 Нейтрализующие моноклональные антитела к il-25 и их применение

Country Status (12)

Country Link
US (1) US11492397B2 (ru)
EP (1) EP3430046A4 (ru)
JP (2) JP7140397B2 (ru)
KR (1) KR102477922B1 (ru)
CN (2) CN109563162B (ru)
AU (1) AU2017234528B2 (ru)
BR (1) BR112018068671A2 (ru)
CA (1) CA3018058A1 (ru)
EA (1) EA201892096A1 (ru)
IL (1) IL261802B2 (ru)
MX (1) MX2018011244A (ru)
WO (1) WO2017160587A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3430046A4 (en) * 2016-03-16 2019-10-23 Abeome Corporation NEUTRALIZING MONOCLONAL ANTIBODIES TO IL-25 AND USES THEREOF
WO2020102935A1 (en) * 2018-11-19 2020-05-28 Suzhou Kanova Biopharmaceutical Co., Ltd. Anti-il-25 antibodies and use thereof
WO2023060144A1 (en) * 2021-10-05 2023-04-13 Lanier Biotherapeutics Monoclonal antibodies to il-25 and uses thereof
WO2024206768A1 (en) * 2023-03-31 2024-10-03 Novarock Biotherapeutics, Ltd. Anti-il-25 antibodies and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006117910A1 (ja) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
US20070237763A1 (en) * 2005-10-06 2007-10-11 Baylor Research Institute Compositions and methods for the treatment of cancer
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0707505D0 (en) * 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
KR101682490B1 (ko) * 2008-07-08 2016-12-05 온코메드 파마슈티칼스, 인크. Ｎｏｔｃｈ-결합제 및 길항제 및 이들의 사용 방법
GB0817891D0 (en) * 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
US9309312B2 (en) * 2008-10-31 2016-04-12 Toray Industries, Inc. Immunoassay method for human CXCL1 protein
US8574582B2 (en) 2008-10-31 2013-11-05 Janssen Biotech, Inc. Methods for mediating fibrotic response
DK2462161T3 (en) * 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
EP2496605A1 (en) * 2009-11-02 2012-09-12 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
US8785605B2 (en) * 2010-03-30 2014-07-22 Janssen Biotech, Inc. Humanized IL-25 antibodies
WO2012045085A1 (en) * 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
AU2012273954A1 (en) * 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
CN104105702B (zh) * 2011-11-16 2016-11-23 昂考梅德药品有限公司 人notch受体突变及其应用
CA2898472C (en) * 2013-02-15 2023-03-07 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
EP3430046A4 (en) * 2016-03-16 2019-10-23 Abeome Corporation NEUTRALIZING MONOCLONAL ANTIBODIES TO IL-25 AND USES THEREOF

Also Published As

Publication number Publication date
IL261802B1 (en) 2023-09-01
CA3018058A1 (en) 2017-09-21
CN109563162A (zh) 2019-04-02
IL261802A (en) 2018-10-31
US20200291105A1 (en) 2020-09-17
WO2017160587A1 (en) 2017-09-21
MX2018011244A (es) 2019-05-30
IL261802B2 (en) 2024-01-01
EP3430046A4 (en) 2019-10-23
EP3430046A1 (en) 2019-01-23
BR112018068671A2 (pt) 2019-07-30
JP2019521132A (ja) 2019-07-25
AU2017234528A1 (en) 2018-11-08
JP7140397B2 (ja) 2022-09-21
AU2017234528A8 (en) 2018-11-29
CN109563162B (zh) 2022-05-24
JP2022184857A (ja) 2022-12-13
KR102477922B1 (ko) 2022-12-14
US11492397B2 (en) 2022-11-08
AU2017234528B2 (en) 2023-09-28
CN115010808A (zh) 2022-09-06
KR20190039469A (ko) 2019-04-12

Similar Documents

Publication Publication Date Title
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
EA201891093A1 (ru) Антитела, специфически связывающие pd-1, и их применение
EA201891992A1 (ru) Химерные рецепторы и способы их применения
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA202091540A1 (ru) Антитела к lilrb2
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201890443A1 (ru) Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201691556A1 (ru) Молекулы антител к tim-3 и их применение
EA201690443A1 (ru) Биспецифические моновалентные диатела, которые способны связываться с cd123 и cd3, и их применения
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения